Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.
Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.
复制标题
头颈癌患者化疗期间发热性中性粒细胞减少症的发生率和预测因素。
DOI:
10.1007/s00520-013-1873-9
复制
发表时间:
2013
影响因子:
3.1
通讯作者:
Inohara H.
中科院分区:
文献类型:
--
作者:
Takenaka Y;Cho H;Yamamoto M;Nakahara S;Yamamoto Y;Inohara H.
PurposeFebrile neutropenia (FN) is an oncologic emergency, and its management is critical during chemotherapy. However, little is known about FN in patients with head and neck cancer. The purpose of this study was to investigate the incidence and predictors of FN in patients with head and neck cancer.MethodsWe performed a retrospective study in a university hospital in Japan between January 2008 and December 2012. Head and neck cancer patients treated with a platinum-based regimen were included in the analysis.ResultsFN occurred in 47 out of 138 cycles, and the incidence of FN was highest during the first cycle. Severe sepsis or more serious events were observed in 46 % of FN episodes. Patients treated with TPF (docetaxel, cisplatin, and fluorouracil) were more susceptible to FN than those treated with DC (docetaxel, cisplatin). The patient-specific risk factors revealed using univariate analysis were tube feeding, the presence of diabetes mellitus, and gastrointestinal adverse effects. Of these, logistic regression analysis demonstrated tube feeding and diabetes mellitus as independent predictors of FN.ConclusionsThe incidence of FN in head and neck cancer patients in the community setting is higher than previously reported. Patients receiving enteral nutrition and those with diabetes are at high risk for FN.